Volume 27, Number 1—January 2021
Synopsis
Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan
Figure 3

Figure 3. Overall crude human papillomavirus prevalence by general primer GP5+/6+-mediated PCR in baseline and repeat surveys in Rwanda (A) and Bhutan (B), with corresponding 95% CIs. Vaccine-targeted types (HPV-6, -11, -16, -18); other α-9 types (HPV-31, -33, -35, -52, -58); other α-7 types (HPV-39, -45, -59, -68); non–α 7/9 types (HPV-26, -51, -53, -56, -66, -70, -73, -82).